CLINICAL TRIAL ACADEMY: ALLA RICERCA DELLA RICETTA PERFETTA-CORSO DI FORMAZIONE IN RICERCA CLINICA 5°EDIZIONE O6-07 OTTOBRE 2026
Settembre 8, 2026/da LuisaALLIANCE AGAINST CANCER 11TH ANNUAL MEETING-NAPLES 10-12 SETTEMBRE 2026
Settembre 8, 2026/da LuisaDARAXONEASIB OR CHEMOTHERAPY IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER.
Settembre 8, 2026/da LuisaAIGOM: 2026 CARCINOMA MAMMARIO METASTATICO: QUALI NOVITA’?-12 OTTOBRE 2026 WEBINAR
Luglio 21, 2026/da LuisaTHERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER WITH DRIVER ALTERATIONS: ASCO LIVING GUIDELINE, 2026.3.1.
Luglio 21, 2026/da LuisaPREDICTING THE PROGNOSIS OF BREAST CANCER BY USING NUTRION-BASED INDEX: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Luglio 14, 2026/da LuisaDEFINING CARDIOVASCULAR ENDPOINTS IN ONCOLOGY TRIALS: CHALLENGES AND OPPORTUNITIES: A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION.
Luglio 7, 2026/da LuisaOPPORTUNISTIC SALPINGECTOMY FOR PREVENTION OF TUBO-OVARIAN CARCINOMA: THE EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY CONSENSUS STATEMENTS.
Giugno 30, 2026/da LuisaTHE PATHOLOGIC RESPONSE EVALUATION AND DETECTION IN CIRCULATING TUMOR-DNA STUDY: ULTRASENSITIVE CIRCULATING TUMOR-DNA ASSESSMENT OF BREAST CANCER MINIMAL RESIDUAL DISEASE.
Giugno 23, 2026/da LuisaFINAL ANALYSIS RESULTS AND PATIENT-REPORTED OUTCOMES FROM DESTINY-LUNG02-A DOSE-BLINDED, RANDOMIZED, PHASE 2 STUDY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-MUTANT METASTATIC NSCLC
Giugno 9, 2026/da LuisaPREVALENCE AND REACTIVATION OF HEPATITIS B AND C IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID TUMORS.
Maggio 26, 2026/da LuisaERADICATION OF HELICOBACTER PYLORI IN THE PRIMARY PREVENTION OF GASTRIC CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Maggio 19, 2026/da Luisa
Scorrere verso l’alto
